Alnylam Pharmaceuticals

Overview

Pioneer siRNA drug company that established GalNAc liver targeting as the dominant delivery mechanism for siRNA, building a portfolio of approved drugs targeting liver-produced proteins after 20+ years of development. Alnylam Pharmaceuticals pioneered GalNAc conjugate delivery of siRNA to liver cells, opening a portfolio of approved drugs targeting liver diseases and liver-produced proteins that affect the heart. Alnylam spent over 20 years before its first drug approval and another 7 years to reach cash-flow break-even, navigating major valuation cycles and toxicity setbacks before the company became sustainably profitable. (Segment 3 (10:00-15:00))